{
  "docId": "019de518-6502-70bc-9a44-c6a9c7f323b5",
  "docSlug": "4230ce80abe7092521a593effe59cbcd",
  "documentTitle": "Oculis | Investor Presentation Deck | 48 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 48,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "other",
  "function": "present_framework",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de518-6502-70bc-9a44-c6a9c7f323b5/31",
  "deckHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5",
  "deckJsonHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5.json",
  "deckAnchorHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.11,
        "x": 0.85,
        "y": 0.035
      },
      "kind": "image",
      "text": "Oculis",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2c282f9-9558-47f5-81e5-7a5bba0d7ab1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.15,
        "x": 0.81,
        "y": 0.49
      },
      "kind": "list",
      "text": "SAFETY ASSESSMENTS\nOphthalmic evaluation & adverse events",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "739c2ce6-dfd2-48fb-8c43-ab8083777660",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.33,
        "w": 0.29,
        "x": 0.06,
        "y": 0.49
      },
      "kind": "list",
      "text": "TRIAL DESIGN\nRandomized, double-masked, vehicle-controlled study\n6-week multi-center trial\n134 participants",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a6c2bd69-cacc-4b40-a81f-89f6efeb6b51",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.29,
        "x": 0.34,
        "y": 0.49
      },
      "kind": "list",
      "text": "PRIMARY ENDPOINT\nChange from baseline in global ocular discomfort score* at Day 29",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e84fae60-4020-47ab-8d50-c3e91530bbbf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.29,
        "x": 0.59,
        "y": 0.49
      },
      "kind": "list",
      "text": "SECONDARY ENDPOINT\nPercentage of high responder# patients at Day 29",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff0a4b6d-5426-42a4-8319-3eb3b430d8ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.019,
        "w": 0.019,
        "x": 0.953,
        "y": 0.95
      },
      "kind": "other",
      "text": "31",
      "attrs": {},
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38c55f52-0bfd-4376-b8ae-f41112dd2a7f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.666,
        "x": 0.167,
        "y": 0.218
      },
      "kind": "paragraph",
      "text": "OBJECTIVES\nPhase 2a trial evaluating the efficacy, safety and tolerability of OCS-02 in reducing ocular symptoms in patients with severe DED",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8144e55e-194c-4c28-aaa3-7eaf6bc80eb4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.46,
        "x": 0.029,
        "y": 0.917
      },
      "kind": "source-note",
      "text": "* Change from baseline in global ocular discomfort score based on the Symptom Assessment iN Dry Eye (SANDE) questionnaire.\n# High responding patients is defined as patients who improve in global ocular discomfort score* by >20 points.\nDED (Dry eye disease).\nShettle L, et al. Clin. Ophthalmol. 2022 ;16:2167-2177.",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1f850ce-7087-4d8d-9ba3-1e254c37064e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.049,
        "w": 0.78,
        "x": 0.029,
        "y": 0.04
      },
      "kind": "title",
      "text": "OCS-02 (Licaminlimab) Phase 2a Trial in Patients with Severe DED",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad402bf0-64e6-4333-82d1-7492a70865a3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "64d6ca59-b2ed-48e3-bde3-103bde1d6200",
      "evidence": "paragraph/paragraph: OBJECTIVES",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}